Relmada: The Bladder Drug Already Worked. The Only Question Left Is the Factory.

Relmada's stock jumped about 40% to roughly $6.23 on March 9, the day it posted strong 12-month data for its bladder cancer drug and announced a $160 million raise. By late June it had given back about a third of that, and it's hovering near $4.50 — not far above the $4.75 that fresh investors paid in the March deal. The reason the market pulled back is a single phrase that kept appearing in the company's update: the application to start the big confirmatory trial has slipped from mid-2026 to the end of 2026, and it's waiting on manufacturing.

That delay is what a "wait and see" rating is built on. It looks, at first glance, like the whole thing is now on the back burner — nothing moves until a factory cooperates. But a manufacturing delay is a different kind of problem than most investors assume, and sorting it out changes what you're actually being asked to judge. So let's separate the three questions the stock now bundles into one: does the drug work, does the company have money, and can it actually get the drug made at scale. Two of those are already answered. Only one is open.

The drug did what it was supposed to do

NDV-01 is a sustained-release version of two chemotherapy drugs — gemcitabine and docetaxel — poured into the bladder to treat a form of bladder cancer that stays in the wall of the organ rather than invading the muscle. The company built it on a drug combination urologists already know, but in a form that releases slowly and can be given in the office without anesthesia.

The numbers that mattered in March came from a Phase 2 trial in which 48 patients were dosed. At 12 months, 76% of the evaluable patients (19 of 25) had a complete response — meaning no detectable high-grade disease — and 95% (36 of 38) had reached a complete response at some point during the study. Among the hardest-to-treat subgroup, patients whose cancer had already failed the standard BCG immunotherapy, 80% still had a complete response at 12 months, and no one in that group went on to need a full bladder removal. The safety print was clean by the company's read: no grade 3 or higher treatment-related adverse events, and no patient stopped treatment because of a side effect.

Two caveats belong in the open. The trial was single-arm and single-center with a small patient count, so the response rates are proof of concept, not confirmation. And the confirmatory trial — the Phase 3 program Relmada is calling RESCUE — has a harder design in at least one arm: a randomized study against no treatment in an intermediate-risk group. Randomized, placebo-controlled trials are where promising Phase 2 results most often get tested against reality, and Relmada says the first 3-month Phase 3 data is not expected before the first half of 2027. The FDA has nonetheless agreed on two paths to approval — a second-line treatment for BCG-unresponsive disease and an adjuvant treatment for intermediate-risk disease — and the formulation's patents run to 2038. The science is intact. That part is not the risk.

The money question is already answered

This is the part that de-risks a lot of the usual biotech worry. As of June 30, 2026, Relmada held $217.7 million in cash and no debt, and the company says that is enough to fund operations through 2029, which it says covers the full Phase 3 RESCUE program. The $160 million gross raise that closed in March — sold at $4.75 per share and, by the company's account, oversubscribed — is what put the balance sheet there, after it stood at $234 million at the end of March.

The cost is real and rising: the quarterly net loss widened to $12.9 million from $9.9 million a year earlier, on higher research and manufacturing spend. But the question of whether Relmada has to raise money again before the Phase 3 top-line data is, on the company's own stated runway, not yet on the table. For a pre-revenue development company, a cash number that clears the pivotal trial's finish line matters more than most multiples ever will.

So what actually slipped

That leaves the only question that's open, and it's narrower than the stock drop suggests. Management's read is that the formulation and the process are already "locked" — the chemistry works and the recipe is set. What is not done is executing actual drug-production (GMP) batches in a quantity big enough to run a trial, collecting the stability data those batches generate, and scheduling the manufacturing slots with outside partners. That is a production and logistics problem, not a science problem. It's the difference between knowing how to make the product and being able to make a lot of it, on a shared calendar, at a vendor, in good enough condition to ship.

Sepranolone, the company's second asset, is on a parallel clock: Relmada expects to file its own trial application by the end of 2026, and it says study sites for a Phase 2 trial in Prader-Willi syndrome are already lined up, waiting on clearance. Two filings, both aimed at year-end 2026, both gated in part by the same kind of manufacturing and regulatory execution.

The one thing that decides it

Here is where I'll be straight, because this is not the setup I'd normally reach for. There is no free-cash-flow bridge in this stock — no revenue, no cash generation, nothing to value it on except the trial that hasn't enrolled yet. I'm carrying the case on cash plus a bounded schedule instead, and that means the uncertainty is higher than a clean FCF story would give you. If the drug fails in Phase 3, the cash buys you time but not a result.

Which makes the decisive proof point unusually concrete and unusually singular. It is not "does it work" or "does it have money" — it is whether Relmada clears the GMP batches and stability data and files the Phase 3 application by year-end 2026. That is the whole tripwire. If the application files on schedule, the program stays on its original clock, the cash still covers the trial, and the stock's drop has mostly been a repricing of a delay that was never a loss of the asset. If it slips again into 2027, or if a later raise becomes necessary before the data, the "through 2029" runway claim and the clean-schedule story both break, and the bear case takes over.

The tape falling 35% on a manufacturing footnote is not the same as the business breaking. But I can be wrong about which kind of delay this is — the honest read is that the science and the cash have cleared, and what's left is one execution date that has to hold. The question the market is now really pricing is whether a factory can deliver on a deadline, not whether the drug is any good.